·  ·  ·  ·  · 

ALPS Group Inc Stock Explodes on Nasdaq Debut – Malaysian Biotech Unicorn Takes Off

1 November 2025
by
ALPS Group Inc Stock Explodes on Nasdaq Debut – Malaysian Biotech Unicorn Takes Off
  • Nasdaq Listing & Debut Price: Alps Group Inc (ticker: ALPS) began trading on Nasdaq on Oct 31, 2025 at roughly $2.55 per share, immediately surging over the day [1]. By close, ALPS traded between $2.40–$2.74 and settled at about $2.56 [2] [3]. This first-day spike represents a massive gain from its SPAC merger valuation base.
  • Trading Volume & Market Cap: First-day volume was modest (≈0.59 million shares) [4]. With ~3.5 million shares outstanding, ALPS’s initial market cap is only on the order of $10–12 million [5], a small figure compared to its $1.6 billion enterprise valuation (EV) set by the SPAC deal [6]. (Finviz data shows $0 revenue and -$2.02 M net income on trailing books [7], typical of an R&D-stage biotech.)
  • Business Combination: ALPS Group’s Nasdaq debut followed completion of its business combination with SPAC Globalink Investment Inc [8]. The merger (approved Oct 7, 2025) created a biotechnology research platform valued at ~$1.6 billion [9] [10]. A concurrent PIPE financing raised US$3.107 million for growth capital (≈310,788 new shares) [11].
  • Leadership & Mission: ALPS is headed by CEO Dr. Tham Seng Kong (also Chairman), who leads a fully-integrated biotech platform in Kuala Lumpur focused on predictive, preventive and precision medicine [12] [13]. The Malaysian science minister noted ALPS is “the country’s first biotechnology firm to reach [unicorn] milestone,” targeting a Nasdaq listing in Q4 2025 with an EV of ~$1.6 billion [14]. In press statements Dr. Tham praised the Nasdaq debut as “a definitive milestone for ALPS… [making] predictive, preventive, and precision medicine… accessible to all” [15].
  • Financial Snapshot: Pre-merger, ALPS Life Sciences (Holdco) had virtually no product revenue and was incurring R&D losses (Finviz reports ~$0 sales and a -$2.0 M net loss) [16]. No quarterly/annual earnings have been released under the new ALPS Group Inc. ticker yet. The SPAC merger brought in cash (cash on hand) and the US$3.1 M PIPE proceeds [17] to fund ALPS’s clinical and expansion plans.
  • Analyst Coverage: There is no published analyst coverage or price targets for ALPS at this stage [18]. Financial sites list “Analysts: n/a” and no 12-month price forecasts [19]. Consequently, market sentiment is driven by biotech SPAC trends and investor enthusiasm for ALPS’s mission, rather than concrete earnings guidance.
  • Sector & Peers: ALPS operates in the biotechnology / life sciences sector, specifically precision medicine (genomics, mRNA vaccines, cell & gene therapies) [20] [21]. It joins a growing Malaysian biotech ecosystem (over 520 biotech firms, ~MYR14.3 billion invested nationally [22]). Globally, ALPS would compete in spirit with firms like Illumina (genetic sequencing) or Moderna (mRNA therapeutics), although ALPS is unique as a Malaysian-based multi-service biotech platform.
  • Risk Factors & Outlook: As a pre-revenue biotech, ALPS faces pipeline risks (clinical trial outcomes, regulatory approvals) and execution challenges. Blank-check mergers have attracted regulatory scrutiny; Reuters noted SPAC deals “had largely fallen out of favor… due to intense scrutiny from regulators” after the 2020–21 boom [23]. Industry observers note that the 2025 SPAC market is more “measured” and selective, with many new SPACs focusing on “AI-driven biotech” and other cutting-edge areas [24]. Any short-term outlook hinges on ALPS meeting R&D milestones and integrating into public markets.

Sources: Company filings and press releases (Oct 31, 2025) [25] [26]; Nasdaq/GlobeNewswire announcements [27] [28]; Reuters (Jan 2024) [29] [30]; TechNode (Malaysia biotech news) [31] [32]; Boardroom Alpha analysis [33]; financial data aggregators (Finviz, StockAnalysis) [34] [35]. (No independent analyst reports found; quotes from company and media are cited.)

Alps Industries share latest news today / कभी भी भाग सकता है
Watch this video on YouTube.

References

1. stockanalysis.com, 2. stockanalysis.com, 3. finviz.com, 4. finviz.com, 5. finviz.com, 6. www.otcmarkets.com, 7. finviz.com, 8. www.otcmarkets.com, 9. www.otcmarkets.com, 10. www.reuters.com, 11. www.globenewswire.com, 12. www.otcmarkets.com, 13. www.nasdaq.com, 14. technode.global, 15. www.otcmarkets.com, 16. finviz.com, 17. www.globenewswire.com, 18. stockanalysis.com, 19. stockanalysis.com, 20. www.nasdaq.com, 21. alps-holdings.com, 22. technode.global, 23. www.reuters.com, 24. www.boardroomalpha.com, 25. www.otcmarkets.com, 26. www.globenewswire.com, 27. www.otcmarkets.com, 28. www.nasdaq.com, 29. www.reuters.com, 30. www.reuters.com, 31. technode.global, 32. technode.global, 33. www.boardroomalpha.com, 34. finviz.com, 35. stockanalysis.com

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Stock Market Today

  • Wall Street Week Ahead: Earnings Focus as US Shutdown Lingers
    November 2, 2025, 1:02 PM EST. Markets gear up for a busy week anchored by Q3 earnings from Palantir, AMD, Shopify, Uber, Amgen, Pfizer, McDonald's, Qualcomm, and Airbnb, with investors also digesting fresh data on September job openings, PMIs, auto sales, and the October employment report. The ongoing US government shutdown could become the longest on record, adding policy uncertainty to price action. On the data calendar, ISM manufacturing/services PMIs, factory orders, and trade metrics are due across the week. Last week, sentiment shifted higher as Amazon's outlook helped lift the Dow, the S&P 500, and the Nasdaq; the Dow +0.09%, S&P +0.26%, Nasdaq +0.61%. For the month, the S&P +2.27%, Nasdaq +4.7%, Dow +2.5%. Gold hovered near $4,000/oz as traders weighed US-China dynamics.
  • Bold Prediction: AMD Could Overtake Broadcom by 2030 and Reach a $1 Trillion Valuation
    November 2, 2025, 12:46 PM EST. Bold thesis: AMD could overtake Broadcom by the end of 2030 and reach a trillion-dollar market cap, up from about $420B today while Broadcom trades near $1.76T. The case rests on AMD gaining traction in data-center GPUs (with lower prices vs. Nvidia), upcoming launches like the MI400X, and a growing AI-infra footprint, including a deal to deploy six gigawatts of AMD chips with OpenAI by 2030. The piece notes AMD's CPU/GPU wins, embedded processors, and applications in autonomous vehicles as potential catalysts. Still, it acknowledges this is a bold call, and execution and broader markets could derail it, but the author argues AI demand and AMD's momentum could power outsized gains over the next five to ten years.
  • Hanesbrands (HBI) Valuation in Focus After Volatility: Is the Stock Undervalued at Current Levels?
    November 2, 2025, 12:20 PM EST. Is Hanesbrands (HBI) still undervalued after recent volatility? The stock has swung this year, with a rally over the past quarter but a negative one-year total return, reflecting shifting investor confidence in the turnaround. The narrative pegs a fair value around $6.47-close to the last close-highlighting a divided view on upside. On the multiple front, Hanesbrands trades at a P/E of 13.8, below the industry average and the implied fair ratio, suggesting potential mispricing or tempered earnings expectations. Key drivers include sustained brand reinvestment, premiumization, and cost-reduction efforts, but ongoing softness in the U.S. core and execution risks remain. The stock may still lure value seekers if growth and margins materialize.
  • The Single Best AI Stock: Could TSMC Surge 148% by 2030?
    November 2, 2025, 12:16 PM EST. Determining the single best AI stock is tough, but the author argues that the future is driven by the AI computing footprint, where hardware makers have the most leverage. The piece pins TSMC (Taiwan Semiconductor Manufacturing) as the standout play, given its role as the world's largest independent foundry and its broad client base-NVIDIA, AMD, Broadcom, Apple. As AI accelerates, TSMC could become essential to virtually every chip design, making it a must-own in the AI arms race. The article also highlights power efficiency gains from the new 2nm node, which can deliver 25%-30% lower power at similar speeds, addressing a key AI bottleneck.
  • Susquehanna Boosts First Solar Target to $285 as Analysts Push Bullish View
    November 2, 2025, 12:10 PM EST. Susquehanna raised its price objective for First Solar (FSLR) from $273 to $285, signaling about 6.8% upside from the latest levels. The move adds to a generally bullish slate: Glj Research restates a Buy with $214.06 target; Goldman Sachs and Wolfe Research also toe the bullish line with $316 and $247 targets, while Guggenheim lifts to $287 and remains Buy. Weiss Ratings keeps a Hold. MarketBeat's consensus is Moderate Buy with an average target of $261.23. At the open, FSLR traded near $266.94; the stock's 52-week range is $116.56-$269.67. Key metrics include market cap $28.63B, P/E 22.83, ROE 15.57%, and EPS of $4.24 last quarter versus $4.32 expected. FY25 guide: $14-$15 EPS; insider sold 686 shares at $182.03.

Related Posts